Arash Farbood

Arash Farbood

Auto-generated profile, based on publicly available information

Arash Farbood

Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in The Journal of Alternative and Complementary Medicine
Verified
Journal Article
Closed access
MSMohammad Ali Sahmeddini
Mohammad Ali Sahmeddini
AFArash Farbood
Arash Farbood
SGSina Ghafaripuor
Sina Ghafaripuor
Background: Electro-acupuncture (EA) can be effective in some pain conditions, but still there have been no randomized controlled studies of EA for treatment of acute postoperative pain in nasal septoplasty. Therefore, we did a study to test whether EA of specific points is superior to sham acupuncture for complementary analgesia after nasal septoplasty. Methods: Ninety (90) patients with an American Society of Anesthesiology (ASA) physical status of I–II scheduled for elective septoplasty were randomly allocated to acupuncture group or control group. Postoperative pain was treated with intravenous meperidine. The time to the first analgesic request, and pain intensity on a 100-mm visual analogue scale (VAS-100) were used to evaluate postoperative pain, and the amount of postoperative meperidine and incidence of analgesia related to side-effects were recorded. Results: Postoperative pain intensity on VAS-100 and respiratory depression were similar in both groups (p > 0.05), but nausea and vomiting were less in the acupuncture group than in the control group (p < 0.05). Conclusions: Findings from our study demonstrate that both uses of EA and 0.1 mg/kg IV morphine given intraoperatively resulted in a similar postoperative pain score, and meperidine was not given in any patient in the two groups during postoperative period because the VAS scores of all patients were less than 40 mm.

7 April 2020 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
AFArash Farbood
Arash Farbood
MSMohammad Ali Sahmeddini
Mohammad Ali Sahmeddini
SBShiva Bayat
Shiva Bayat
NKNazanin Karami
Nazanin Karami

1 May 2019 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
MSMohammad Ali Sahmeddini
Mohammad Ali Sahmeddini
MKMohammad Bagher Khosravi
Mohammad Bagher Khosravi
AFArash Farbood
Arash Farbood
Introduction and Aims: Patients with opioid use disorder experience great challenges during acute pain management due to opioid tolerance or withdrawal symptoms. Previous studies have recommended the use of adjuvant drugs in these patients. In this study, we compared the effect of intraoperative lidocaine with ketamine in postoperative pain management of these patients. Design and Methods: In this randomized clinical trial, 180 patients with opioid use disorder who underwent orthopedic surgery under general anesthesia were randomly allocated into 3 groups. Patients in groups A, B, and C received intravenous lidocaine, ketamine, or normal saline, respectively, during the operation. Then, postoperative pain scores, analgesic requirements, patient satisfaction, and patient sleepiness were recorded and compared among the 3 groups. Results: Numerical rating scales during the first hour postoperation were significantly lower in the lidocaine group than in the ketamine or control group (P < 0.001). The mean total amount of morphine consumption during the first 24-hour postoperation was 14.49 ± 26.89, 16.59 ± 30.65, and 21.72 ± 43.29 mg in the lidocaine, ketamine, and control group, respectively, being significantly lower in the lidocaine group in comparison with the other groups (P < 0.001). Patients in the lidocaine group were less restless, calmer, and less drowsy than patients in the ketamine and control group (P < 0.001). Discussion and Conclusion: According to these findings, systemic lidocaine is more effective than systemic ketamine to improve the quality of acute pain management without causing any significant complications in patients with opioid use disorder.


1 December 2015 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Open access
PDF file
ATArman Taheri
Arman Taheri
AFArash Farbood
Arash Farbood
RHRamin Heshmat
Ramin Heshmat
ASAfshin Samadi
Afshin Samadi
PKPatricia Khashayar
Patricia Khashayar
GKGhazaleh Ebrahimi Khaneqah
Ghazaleh Ebrahimi Khaneqah
Background: Despite high prevalence of diabetic peripheral neuropathy there is no definite treatment for the condition. The present study was conducted to assess the efficacy of transdermal nitroglycerin patch in pain control of patients with DPN.Methods: This randomized, double-blind, crossover study was conducted on 30 patients with symmetric distal peripheral neuropathy and good glycemic control. The patients were randomly assigned to receive nitroglycerin transdermal and placebo patches in two 4-week stages. The severity of pain and other neuropathic sensory symptoms were assessed at the end of each course.Results: Mean reduction of pain severity was more prominent in the NTG group compared to placebo group of the study (p= 0.048) at least during the first phase of the study. Except for mood and sleep, a significant reduction in all Brief Pain Inventory scores was noted in the drug group (all correctedp< 0.05). SF-MPQ also showed the drug patch to be effective in improving different aspects of pain measured using McGill Pain Questionnaire, except for Role–emotional.Conclusions: It could be concluded that nitroglycerin plasters can effectively help alleviate pain in patients with diabetic neuropathy.Trial registration: IRCT201308223213N1